Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say

Moderna and Merck graded their own vaccine's homework, and it passed.

An experimental vaccine kept melanoma from returning or spreading in people at high risk of the skin cancer recurring, drugmakers Moderna and Merck announced Wednesday.